Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.32 -0.08 (-0.85%) Market Cap: 2.84 Bil Enterprise Value: 2.52 Bil PE Ratio: 0 PB Ratio: 3.67 GF Score: 39/100

Iovance Biotherapeutics Inc to Provide Melanoma Regulatory and Clinical Updates Call Transcript

Apr 06, 2022 / 12:00PM GMT
Release Date Price: $16.94 (+2.29%)
Operator

Good day, and thank you for standing by. Welcome to the Iovance Biotherapeutics Investor Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Sara Pellegrino, Vice President, Invest, Public Relations. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good morning, and thank you for joining us to discuss regulatory and clinical updates for lifileucel in metastatic melanoma.

During today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will highlight the positive FDA feedback on our potency assay matrix to support our planned BLA submission. Then Dr. Friedrich Finckenstein, our Chief Medical Officer, will further define our strategy for TIL combination therapy in front-line melanoma.

Following these updates, we will hold a Q&A session. Additional Iovance team members taking part in the Q&A include Jean-Marc Bellemin,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot